がん支持療法薬の市場規模-薬剤クラス別、がんタイプ別、流通チャネル別、世界予測 2023年～2032年

がん支持療法薬の市場規模は、世界のがん罹患率の上昇により、2023年から2032年までのCAGRが1.9%になると予測されています。

米国がん統計局のデータによると、2020年には新たに150万人以上のがん患者が報告され、そのうち60万2,347人近くが死亡したと報告されています。がん患者数が増加の一途をたどるなか、化学療法や放射線療法など、がん治療の副作用を緩和する治療法の需要が急増しています。

さらに、がん治療中のQOL（生活の質）の重要性に対する意識の高まりが、これらの薬剤の使用に拍車をかけています。患者が症状を管理し、より高いレベルの快適さと幸福感を維持する方法を求めるにつれて、がん支持療法ソリューションが支持を集めると思われます。

がん支持療法薬市場は、薬剤クラス別、がんの種類別、流通チャネル別、地域別に分類されます。

オピオイド分野は、2023年から2032年にかけて約2.4％のCAGRで成長すると予想されています。オピオイドはがん関連の疼痛管理に有効であることが知られているため、がん治療中の患者に処方されるケースが増えています。オピオイド製剤の進歩に伴い、副作用を最小限に抑えながら最適な鎮痛効果を得ることに焦点が移っています。これは患者の快適性を高めるだけでなく、がん症状の管理により包括的なアプローチを提供することになります。

肺がんは、最も罹患率が高く侵攻性の高いがんの1つであるため、2023年から2032年にかけてCAGR 2.5％が予測されています。肺がん患者は、痛み、息苦しさ、疲労感など、さまざまな苦痛を伴う症状に悩まされることが多いです。そのため、肺がん患者特有のニーズに合わせた支持療法薬の需要が高いです。患者の生活の質を向上させるための肺がんに対する革新的な薬剤や治療法の開発が、業界の成長を牽引しています。

北米のがん支持療法薬業界は、強固なヘルスケアインフラ、広範な研究開発活動、高いがん罹患率に支えられ、2023年から2032年にかけてCAGR 1.7%の成長が見込まれています。米国とカナダはがん支持療法推進の最前線にあり、研究開発に多額の投資を行い、患者が最新かつ最も効果的な支持療法薬を利用できるようにしています。北米では、がん治療中の患者の快適さと幸福が重視されており、今後も市場拡大の原動力となると思われます。

目次

第1章 調査手法と調査範囲

第2章 エグゼクティブサマリー

第3章 がん支持療法薬市場、業界洞察

• エコシステム分析
• 業界への影響要因
  • 成長促進要因
    • がんの罹患率および有病率の上昇
    • がん治療における技術進歩の増加
    • 高齢者人口の増加
    • デジタルヘルス統合の進展
    • 支持療法薬の利用可能性と利点に関する患者やヘルスケア専門家の意識の高まり
  • 業界の潜在的リスク＆課題
    • 代替療法や補完療法の利用可能性
    • 限られたヘルスケア資源
    • 副作用医薬品
• 成長可能性分析
• COVID-19の影響分析
• 規制状況
• ポーターの分析
• PESTEL分析

第4章 競合情勢

• イントロダクション
• 企業マトリックス分析
• 企業ポジショニングマトリックス
• 主要市場企業の競合分析
• 戦略ダッシュボード

第5章 がん支持療法薬の市場規模・予測：薬剤クラス別

• 主要動向：薬剤クラス別
• G-CSFs（顆粒球コロニー刺激因子）
• ESAs（赤血球造血刺激因子）
• 制吐剤
• ビスフォスフォネート
• オピオイド
• 非ステロイド性抗炎症薬
• その他の薬剤

第6章 がん支持療法薬の市場規模・予測：がんタイプ別

• 主要動向：がんタイプ別
• 乳がん
• 肺がん
• メラノーマ
• 前立腺がん
• 大腸がん
• 肝臓がん
• 胃がん
• その他のがん

第7章 がん支持療法薬の市場規模・予測：流通チャネル別

• 主要動向：流通チャネル別
• 病院薬局
• ドラッグストア・小売薬局
• オンライン薬局

第8章 がん支持療法薬の市場規模・予測：地域別

• 主要動向：地域別
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • その他中東とアフリカ

第9章 企業プロファイル

• Amgen, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Heron Therapeutics, Inc.
• Novartis AG
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Helsinn Healthcare SA
• Teva Pharmaceuticals Industries Ltd.
• Fagron Group

Data Tables

• TABLE 1 Product mapping
• TABLE 2 Market revenue, by drug class (2022)
• TABLE 3 Market share, by cancer type (2022)
• TABLE 4 Market share, by distribution channel (2022)
• TABLE 5 Global cancer supportive care drugs market size, by region, 2018-2022 (USD Million)
• TABLE 6 Global cancer supportive care drugs market size, by region, 2023-2032 (USD Million)
• TABLE 7 Global cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 8 Global cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 9 Global cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 10 Global cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 11 Global cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 12 Global cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 13 Industry impact forces
• TABLE 14 G-CSFs (Granulocyte-colony Stimulating Factors) market size, 2018-2022 (USD Million)
• TABLE 15 G-CSFs (Granulocyte-colony Stimulating Factors) market size, 2023-2032 (USD Million)
• TABLE 16 ESAs (Erythropoiesis Stimulating Agents) market size, 2018-2022 (USD Million)
• TABLE 17 ESAs (Erythropoiesis Stimulating Agents) market size, 2023-2032 (USD Million)
• TABLE 18 Anti-emetics market size, 2018-2022 (USD Million)
• TABLE 19 Anti-emetics market size, 2023-2032 (USD Million)
• TABLE 20 Bisphosphonates market size, 2018-2022 (USD Million)
• TABLE 21 Bisphosphonates market size, 2023-2032 (USD Million)
• TABLE 22 Opioids market size, 2018-2022 (USD Million)
• TABLE 23 Opioids market size, 2023-2032 (USD Million)
• TABLE 24 NSAIDs market size, 2018-2022 (USD Million)
• TABLE 25 NSAIDs market size, 2023-2032 (USD Million)
• TABLE 26 Other drugs market size, 2018-2022 (USD Million)
• TABLE 27 Other drugs market size, 2023-2032 (USD Million)
• TABLE 28 Breast cancer market size, 2018-2022 (USD Million)
• TABLE 29 Breast cancer market size, 2023-2032 (USD Million)
• TABLE 30 Lung cancer market size, 2018-2022 (USD Million)
• TABLE 31 Lung cancer market size, 2023-2032 (USD Million)
• TABLE 32 Melanoma market size, 2018-2022 (USD Million)
• TABLE 33 Melanoma market size, 2023-2032 (USD Million)
• TABLE 34 Prostate cancer market size, 2018-2022 (USD Million)
• TABLE 35 Prostate cancer market size, 2023-2032 (USD Million)
• TABLE 36 Stomach cancer market size, 2018-2022 (USD Million)
• TABLE 37 Stomach cancer market size, 2023-2032 (USD Million)
• TABLE 38 Liver cancer market size, 2018-2022 (USD Million)
• TABLE 39 Liver cancer market size, 2023-2032 (USD Million)
• TABLE 40 Colorectal cancer market size, 2018-2022 (USD Million)
• TABLE 41 Colorectal cancer market size, 2023-2032 (USD Million)
• TABLE 42 Other cancer types market size, 2018-2022 (USD Million)
• TABLE 43 Other cancer types market size, 2023-2032 (USD Million)
• TABLE 44 Hospital pharmacies market size, 2018-2022 (USD Million)
• TABLE 45 Hospital pharmacies market size, 2023-2032 (USD Million)
• TABLE 46 Drug stores and retail pharmacies market size, 2018-2022 (USD Million)
• TABLE 47 Drug stores and retail pharmacies market size, 2023-2032 (USD Million)
• TABLE 48 Online pharmacies market size, 2018-2022 (USD Million)
• TABLE 49 Online pharmacies market size, 2023-2032 (USD Million)
• TABLE 50 North America cancer supportive care drugs market size, by country, 2018-2022 (USD Million)
• TABLE 51 North America cancer supportive care drugs market size, by country, 2023-2032 (USD Million)
• TABLE 52 North America cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 53 North America cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 54 North America cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 55 North America cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 56 North America cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 57 North America cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 58 U.S. cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 59 U.S. cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 60 U.S. cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 61 U.S. cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 62 U.S. cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 63 U.S. cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 64 Canada cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 65 Canada cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 66 Canada cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 67 Canada cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 68 Canada cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 69 Canada cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 70 Europe cancer supportive care drugs market size, by country, 2018-2022 (USD Million)
• TABLE 71 Europe cancer supportive care drugs market size, by country, 2023-2032 (USD Million)
• TABLE 72 Europe cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 73 Europe cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 74 Europe cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 75 Europe cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 76 Europe cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 77 Europe cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 78 Germany cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 79 Germany cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 80 Germany cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 81 Germany cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 82 Germany cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 83 Germany cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 84 U.K. cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 85 U.K. cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 86 U.K. cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 87 U.K. cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 88 U.K. cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 89 U.K. cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 90 France cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 91 France cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 92 France cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 93 France cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 94 France cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 95 France cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 96 Spain cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 97 Spain cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 98 Spain cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 99 Spain cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 100 Spain cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 101 Spain cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 102 Italy cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 103 Italy cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 104 Italy cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 105 Italy cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 106 Italy cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 107 Italy cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 108 Rest of Europe cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 109 Rest of Europe cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 110 Rest of Europe cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 111 Rest of Europe cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 112 Rest of Europe cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 113 Rest of Europe cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 114 Asia Pacific cancer supportive care drugs market size, by country, 2018-2022 (USD Million)
• TABLE 115 Asia Pacific cancer supportive care drugs market size, by country, 2023-2032 (USD Million)
• TABLE 116 Asia Pacific cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 117 Asia Pacific cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 118 Asia Pacific cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 119 Asia Pacific cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 120 Asia Pacific cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 121 Asia Pacific cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 122 Japan cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 123 Japan cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 124 Japan cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 125 Japan cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 126 Japan cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 127 Japan cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 128 China cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 129 China cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 130 China cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 131 China cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 132 China cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 133 China cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 134 India cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 135 India cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 136 India cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 137 India cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 138 India cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 139 India cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 140 Australia cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 141 Australia cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 142 Australia cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 143 Australia cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 144 Australia cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 145 Australia cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 146 Rest of Asia Pacific cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 147 Rest of Asia Pacific cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 148 Rest of Asia Pacific cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 149 Rest of Asia Pacific cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 150 Rest of Asia Pacific cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 151 Rest of Asia Pacific cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 152 Latin America cancer supportive care drugs market size, by country, 2018-2022 (USD Million)
• TABLE 153 Latin America cancer supportive care drugs market size, by country, 2023-2032 (USD Million)
• TABLE 154 Latin America cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 155 Latin America cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 156 Latin America cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 157 Latin America cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 158 Latin America cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 159 Latin America cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 160 Brazil cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 161 Brazil cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 162 Brazil cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 163 Brazil cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 164 Brazil cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 165 Brazil cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 166 Mexico cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 167 Mexico cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 168 Mexico cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 169 Mexico cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 170 Mexico cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 171 Mexico cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 172 Rest of Latin America cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 173 Rest of Latin America cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 174 Rest of Latin America cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 175 Rest of Latin America cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 176 Rest of Latin America cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 177 Rest of Latin America cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 178 Middle East & Africa cancer supportive care drugs market size, by country, 2018-2022 (USD Million)
• TABLE 179 Middle East & Africa cancer supportive care drugs market size, by country, 2023-2032 (USD Million)
• TABLE 180 Middle East & Africa cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 181 Middle East & Africa cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 182 Middle East & Africa cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 183 Middle East & Africa cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 184 Middle East & Africa cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 185 Middle East & Africa cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 186 South Africa cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 187 South Africa cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 188 South Africa cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 189 South Africa cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 190 South Africa cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 191 South Africa cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 192 Saudi Arabia cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 193 Saudi Arabia cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 194 Saudi Arabia cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 195 Saudi Arabia cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 196 Saudi Arabia cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 197 Saudi Arabia cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)
• TABLE 198 Rest of Middle East & Africa cancer supportive care drugs market size, by drug class, 2018-2022 (USD Million)
• TABLE 199 Rest of Middle East & Africa cancer supportive care drugs market size, by drug class, 2023-2032 (USD Million)
• TABLE 200 Rest of Middle East & Africa cancer supportive care drugs market size, by cancer type, 2018-2022 (USD Million)
• TABLE 201 Rest of Middle East & Africa cancer supportive care drugs market size, by cancer type, 2023-2032 (USD Million)
• TABLE 202 Rest of Middle East & Africa cancer supportive care drugs market size, by distribution channel, 2018-2022 (USD Million)
• TABLE 203 Rest of Middle East & Africa cancer supportive care drugs market size, by distribution channel, 2023-2032 (USD Million)

Charts & Figures

• FIG 1 GMI report coverage: Critical research elements
• FIG 2 Top-down approach
• FIG 3 Market estimation and forecast methodology
• FIG 4 Market forecasting methodology
• FIG 5 Breakdown of primary participants
• FIG 6 Cancer supportive care drugs industry 36 degree synopsis, 2018 - 2032
• FIG 7 Growth potential analysis, by drug class
• FIG 8 Growth potential analysis, by cancer type
• FIG 9 Growth potential analysis, by distribution
• FIG 10 Porter's analysis
• FIG 11 PESTEL analysis
• FIG 12 Company matrix analysis, 2022
• FIG 13 Competitive analysis of major market players, 2022
• FIG 14 Competitive positioning matrix, 2022
• FIG 15 Strategic dashboard, 2022

Cancer supportive care drugs market size is predicted to witness 1.9% CAGR from 2023 to 2032 due to the escalating incidence of cancer worldwide. According to the data from the United States Cancer Statistics, more than 1.5 million new cancer cases were reported in 2020, out of which nearly 602,347 deaths were reported. As the number of cancer cases continues to rise, the demand for therapies that alleviate the side effects of cancer treatment, such as chemotherapy and radiation therapy, is surging.

Additionally, the growing awareness about the importance of quality of life during cancer treatment has fueled the usage of these drugs. As patients seek ways to manage their symptoms and maintain a higher level of comfort and well-being, the cancer support care solutions will gain traction.

Cancer supportive care drugs market is divided based on drug class, cancer type, distribution channel, and region.

The opioids segment is expected to record around 2.4% CAGR from 2023 to 2032. As opioids are known for their effectiveness in managing cancer-related pain, they are increasingly prescribed to patients undergoing cancer treatment. With advancements in opioid formulations, the focus has shifted toward achieving optimal pain relief while minimizing side effects. This is not only enhancing patient comfort but also providing a more comprehensive approach to managing cancer symptoms.

The lung cancer segment is anticipated to observe 2.5% CAGR during 2023 and 2032 as it is one of the most prevalent and aggressive types of cancer. Patients with lung cancer often suffer from a range of distressing symptoms, including pain, breathlessness, and fatigue. As a result, there is a high demand for supportive care drugs tailored to the specific needs of lung cancer patients. The development of innovative drugs and therapies for lung cancer for improving the quality of life for patients is driving the industry growth.

North America cancer supportive care drugs industry is expected to witness 1.7% CAGR from 2023 to 2032, favored by a robust healthcare infrastructure, extensive R&D activities, and high cancer prevalence. The United States and Canada are at the forefront of advancing cancer supportive care, investing heavily in R&D, and ensuring that patients have access to the latest and most effective supportive care drugs. The emphasis on patient comfort and well-being during cancer treatment in North America will continue to drive the market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 COVID-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Global cancer supportive care drugs market 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Drug class trends
  • 2.1.4 Cancer type trends
  • 2.1.5 Distribution channel trends

Chapter 3 Cancer Supportive Care Drugs Market Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence and prevalence of cancer
    • 3.2.1.2 Increasing technological advancements in cancer therapies
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Growing integration of digital health
    • 3.2.1.5 Increasing awareness among patients and healthcare professionals about the availability and benefits of supportive care drugs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Availability of alternative therapies or complementary treatments
    • 3.2.2.2 Limited healthcare resources
    • 3.2.2.3 Adverse effect drugs
• 3.3 Growth potential analysis
  • 3.3.1 By drug class
  • 3.3.2 By cancer type
  • 3.3.3 By distribution channel
• 3.4 COVID- 19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Company positioning matrix, 2022
• 4.4 Competitive analysis of major market players, 2022
• 4.5 Strategy dashboard, 2022

Chapter 5 Cancer Supportive Care Drugs Market Size and Forecast, By Drug class (USD Million)

• 5.1 Key trends, by drug class
• 5.2 G-CSFs (Granulocyte-colony Stimulating Factors)
• 5.3 ESAs (Erythropoiesis Stimulating Agents)
• 5.4 Anti-emetics
• 5.5 Bisphosphonates
• 5.6 Opioids
• 5.7 NSAIDs
• 5.8 Other drugs

Chapter 6 Cancer Supportive Care Drugs Market Size and Forecast, By Cancer type (USD Million)

• 6.1 Key trends, by cancer type
• 6.2 Breast cancer
• 6.3 Lung cancer
• 6.4 Melanoma
• 6.5 Prostate cancer
• 6.6 Colorectal cancer
• 6.7 Liver cancer
• 6.8 Stomach cancer
• 6.9 Other cancer types

Chapter 7 Cancer Supportive Care Drugs Market Size and Forecast, By Distribution channel (USD Million)

• 7.1 Key trends, by distribution channel
• 7.2 Hospital pharmacies
• 7.3 Drug stores and retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Cancer Supportive Care Drugs Market Size and Forecast, By Region (USD Million)

• 8.1 Key trends, by region
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East & Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

• 9.1 Amgen, Inc.
• 9.2 Merck & Co., Inc.
• 9.3 Johnson & Johnson Services, Inc.
• 9.4 Heron Therapeutics, Inc.
• 9.5 Novartis AG
• 9.6 GSK plc
• 9.7 F. Hoffmann-La Roche Ltd.
• 9.8 Helsinn Healthcare SA
• 9.9 Teva Pharmaceuticals Industries Ltd.
• 9.10 Fagron Group